74 results about "Differentiation Inducer" patented technology

The novel benzamide derivative represented by formula (1) and the novel anilide derivative represented by formula (13) of this invention has differentiation-inducing effect, and are, therefore, useful a therapeutic or improving agent for malignant tumors, autoimmune diseases, dermatologic diseases and parasitism. In particular, they are highly effective as an anticancer drug, specifically to a hematologic malignancy and a solid carcinoma.

The invention provides an inducing method and inducing culture medium for differentiation of bone marrow mesenchymal stem cells into osteoblasts in vitro. The inducing culture medium is composed of 1*10<-8> mol/L of dexamethasone, 50 mu mol/L of ascorbic acid and 10 mmol/L of sodium beta-glycerophosphate; and solvent is a supernatant of a sclerite complete culture medium and comprises 10% of fetal calf serum, 100 U/mL of penicillin, 100 mg/L of streptomycin, a mixture of DMEM culture fluid and F12 culture fluid and multiple growth factors secreted by bone cells in the sclerite culture process. According to the invention, bone marrow mesenchymal stem cells of a mouse are purified by replacing the cell culture fluid through an adherent cell passage method, the obtained cells of the first generation are induced, and the supernatant of the sclerite complete culture medium cultured for 72-96 hours is used as the solvent of osteoblast differentiation inducer, thereby obviously improving the in vitro osteogenic differentiation efficiency of bone marrow mesenchymal stem cells.

The invention relates to a method of inducing and differentiating human umbilical cord derived mesenchymal stem cells into cartilage cells. The method includes: in order to solve the problem that the prior art is low in differentiation efficiency, cleaning umbilical cord tissue to remove blood stain, cutting the same into small sections, dissecting the small sections to remove vascular tissue, cutting the small sections into pieces, and digesting to obtain a single mesenchymal stem cell; culturing the obtained mesenchymal stem cell in an amplification manner to the seventh generation to obtain a unicellular suspension, inoculating the unicellular suspension into a serum-free culture medium containing a cartilage differentiation inducer to continue culturing, replacing a fresh culture medium every other 3.5 days, and inducing for 14 days to obtain the cartilage cells. The method can efficiently differentiate the umbilical cord mesenchymal stem cells into the cartilage cells and is of important significance in the aspects of restoring cartilage tissue in human bodies and treating bone injury.

The present invention relates to new use of natural medicine, and is the new use of natural abscisic acid in tumor treating medicine, and especially the new use of natural abscisic acid in preparing tumor cell differentiation inducing agent. Natural abscisic acid in the concentration of 1 microgram/L to g/L can inhibit the proliferation of tumor cell and induce the transformation of tumor cell to normal cell effectively. The present invention has the advantages of simple operation, high effect, less toxic side effect, etc.

The present invention provides a method for producing mesenchymal cells for production of mesenchymal cells for formation of a tooth, the method comprising: culturing totipotent stem cells in the presence of a differentiation inducer to produce a cell population after differentiation induction treatment, the cell population containing CD44-positive and CD29-positive cells or CD44-positive and CD 106-positive cells; and selecting, from the cell population after the differentiation induction treatment, the CD44-positive and CD29-positive cells or CD44-positive and CD 106-positive cells as the mesenchymal cells for the formation of the tooth. The present invention also provides a method for producing a tooth comprising: positioning, in a support carrier capable of retaining cells in a state of contacting therewith, a first cell mass substantially consisting of only either one of mesenchymal cells and epithelial cells and a second cell mass substantially consisting of only the other one of the mesenchymal cells and epithelial cells, the first and second cell masses being not mixed with each other but made to closely contact with each other; and culturing the first and second cell masses; wherein the mesenchymal cells comprise the mesenchymal cells for the formation of the tooth.

The invention relates to an induction method for promoting differentiation of human umbilical cord mesenchymal stem cells into chondrocytes, which comprises the following steps of: obtaining an umbilical cord tissue block, a primary culturing stem cells, subculturingstem cells and inducing stem cells differentiate to chondrocytes, wherein the induction for differentiation of stem cellsinto chondrocytes comprises the following steps of: resuspending human umbilical cord mesenchymal stem cells subcultured to a seventh generation by adopting a serum-free culture medium to prepare P7 generation stem cell suspension; inoculating P7 generation stem cell suspension into the serum-free culture medium containing a cartilage differentiation inducer for continuous culture; replacing the serum-free culture medium containing the cartilage differentiation inducer in a half amount every three days; obtaining chondrocytes after 14 days.The induction method can differentiate human umbilical cord mesenchymal stem cells into chondrocytes,which has important significance in repairing human cartilage tissues and treating bone injuries.

The invention relates to the use of certain PDE4 inhibitors alone or in combination with one or more differentiation inducing agents and/or an agent effective in raising intracellular concentrations of cAMP or a stable analogue of cAMP in the preparation of pharmaceutical compositions for the treatment of neoplasms of lymphoid cells.

The purpose is to select low-molecular-weight compounds which are effective in inducing differentiation of mesenchymal stem cell into hepatocyte and to develop a safe differentiation-inducing method having excellent efficiency of differentiating mesenchymal stem cell into hepatocyte. Provided are at least one compound selected from the group consisting of compounds represented by formulae (1) and (2), a salt thereof, or a solvate of them; a differentiation inducer comprising at least one compound selected from the group consisting of compounds represented by formulae (1) and (2), a salt thereof, or a solvate of them; and a differentiation inducer comprising a compound represented by formula (8), a salt thereof, or a solvate of them.

The invention discloses application of a water-soluble realgar solid dispersoid in preparation of a bone marrow hematopoietic stem/progenitor cell erythroid differentiation inducer. The realgar soliddispersoid is prpeared from the following raw materials in parts by weight: 1 part of realgar, 1 to 20 parts of macromolecule and 0 to 5 parts of surfactant. According to the application disclosed bythe invention, the situation that the water-soluble realgar solid dispersoid can induce bone marrow hematopoietic stem cells/progenitor cells to differentiate toward erythrocytes is found, so that accumulation of erythroid cell in bone marrow cells is promoted, and the reduction of the quantity of the erythrocytes caused by the bone marrow hematopoietic stem/progenitor cell erythroid differentiation is effectively alleviated, anemia caused by hematopoietic obstacle is improved, and simultaneously, the bone marrow cells can be protected from being killed by medicines.

The invention belongs to the technical field of medicines, and discloses application of isoliquiritigenin to prepare medicaments of inducing a tumor to be differentiated. Tests prove that when the concentration of the isoliquiritigenin is low, the isoliquiritigenin cannot kill the tumor cells, but has the action of reversing the tumor cells in leukemia, liver cancer, malignant melanoma and the like into the cell with normal functions. Based on the characteristics, the isoliquiritigenin is mixed with other medical auxiliary materials to prepare an oral or injectable preparation; when the oral or the injectable preparation is clinically used for treating various malignant tumors, the preparation has the advantages of confirmed curative effect, no obvious toxic and side effects, and the suitability for long-period and continuous medicine-taking; and the medicament prepared by the isoliquiritigenin is obviously better than the prior medicament clinically used for treating the tumors,.

The invention relates to a method for preparing a human umbilical cord mesenchymal stem cell injection for treating ischemic femoral head necrosis by cavity injection. The method comprises the steps of obtaining an umbilical tissue block, performing primary culture of stem cells, subculturing the stem cells, and preparing the human umbilical cord mesenchymal stem cell injection. The method for preparing the human umbilical cord mesenchymal stem cell injection comprises resuspending the Pe-generation human umbilical cord mesenchymal stem cells with a compound electrolyte injection, and repeatedly purging; after the Pe-generation human umbilical cord mesenchymal stem cell suspension is uniform, supplementing the compound electrolyte injection to adjust the concentration of the human umbilical cord mesenchymal stem cells to 4*10<4-6>*10<4> cells/mL, and adding an osteogenic differentiation inducer, to obtain the human umbilical cord mesenchymal stem cell injection, wherein e is equal to 6, 7, 8, 9, and 10. The human umbilical cord mesenchymal stem cells can be differentiated into osteoblasts, and the method has important significance in repairing human bone formation tissue and treating bone damage.

The invention provides microRNA used for inducing leukemia cell differentiation and application thereof in the induction of erythroid differentiation of tumor cell lines K562. The microRNA not only has the advantages of cheapness, no toxic or side effect, long duration, high transfection efficiency and the like, but also has the characteristics of stronger action and effectiveness of various indexes for tumor cell differentiation compared with a conventional human leukemia cell erythroid differentiation siRNA inducer.

The present invention relates to a pharmaceutical composition for the treatment and prevention of cancer and the preparation method thereof, especially to a cell differentiation agent named CDA-II which is prepared by reverse phase chromatography of fresh human urine. The pharmaceutical composition is effective for the treatment and prevention of cancer. The active components in CDA-II contain differentiation inducers, differentiation helper inducers and an anticachexia agent, which act cooperatively to achieve the best therapeutic effect.

A synthetic peptide having a stem cell differentiation-inducing activity to induce differentiation of pluripotent stem cells into endodermal cells, a stem cell differentiation inducer having this peptide as an active ingredient, and a method for inducing differentiation of pluripotent stem cells using these. The synthetic peptide provided by the present invention contains a stem cell differentiation-inducing peptide sequence, and this stem cell differentiation-inducing peptide sequence is selected from an amino acid sequence constituting a signal peptide in any of amyloid precursor proteins (APP), amyloid precursor-like protein (APLP) 1 and APLP2, which are known as proteins belonging to the APP family, a partial amino acid sequence an amino acid sequence constituting this signal peptide, or a modified amino acid sequence formed by substitution, deletion and/or addition of 1, 2 or 3 amino acid residues in these amino acid sequences.

A novel composition and health food having a good pharmacological activity and which can be readily absorbed through an alimentary canal are provided. The composition induced apoptosis of cells and includes an agaricus extract. The composition may further comprise a pharmaceutically acceptable carrier. Typically, the cells are cancer cells. The composition may further include a differentiation inductionagent. Preferably, the differentiation induction agent is a vitamin A derivative. The vitamin A derivative may be tretinoin. The agaricus extract may include a main fraction eluted chromatographically of a molecular weight of 100 to 2000, which is obtained by the steps of extraction with hot water from a fruiting body of agaricus, dialyzing the extract and performing a,chromatography process on the dialyzate.

The invention discloses an autophagy-based stem cell myocardial cell induced differentiation method and an application thereof. The method comprises the following steps of step 1, preparing an autophagy inducer wherein, the autophagy inducer dissolves in DMSO to prepare mother liquor, the mother liquor is stored at 20 DEG C, a solvent DMSO with the concentration being 0.01% is served as a controlgroup, and the mother liquor is added once when liquor is changed; step 2, stem cell culture; step 3, a first stage for stem cell induction, wherein a myocardial differentiation inducer is added, andcomprises the autophagy inducer prepared in the step 1 and vitamin C; step 4, a second stage for stem cell induction, wherein after good embryoid bodies are obtained through suspension culture, embryoid bodies are transferred into a cell culture plate for adherent culture, the induced culture solution is the same as that in the first stage, the liquor is exchanged each day or every two days according to the cell growth condition, and as time goes on, spontaneous rhythmic jump of the embryoid bodies is observed. The method improves the induced differentiation efficiency and is suitable for popularization and application.

The object of the invention is to provide a technique of suppressing tumorigenesis in IPS cells and inducing differentiation into target differentiated cells. In use of a statin and a differentiation inducer, iPS cells are differentiated into target differentiated cells, whereby iPS cells can be differentiated into differentiated cells in which tumorigenesis is suppressed.